Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions, the method helps select the most advantageous regimen for individual patients. GlobalData’s report on Yakult Honsha gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Yakult Honsha, Cancer treatment biomarkers was a key innovation area identified from patents. Yakult Honsha's grant share as of February 2024 was 64%. Grant share is based on the ratio of number of grants to total number of patents.
Method to select folfox or folfiri regimen for colorectal cancer
See Also:
A recently granted patent (Publication Number: US11879150B2) outlines a selection method for determining the appropriate regimen, FOLFOX or FOLFIRI, for treating colorectal cancer based on specific genetic markers. The method involves measuring the copy number gain in various regions on human chromosomes in tumor tissue specimens. If the copy number gain is detected in certain regions like 7q34, 8q24.1, 8q24.2, among others, the FOLFIRI regimen is selected for treatment. Conversely, if no gain is observed in the 9q34.3 region, the FOLFIRI regimen is chosen. Additionally, if a gain is detected in the 7p15.3 region but not in the 8q24.1 region, the FOLFOX regimen is recommended for treatment.
Furthermore, the patent details a method for selecting between FOLFOX and FOLFIRI regimens based on the copy number gain in specific regions on human chromosomes, such as 7q34, 8q24.1, 8q24.2, among others. If a copy number gain is identified in these regions, the FOLFIRI regimen is chosen for treating colorectal cancer in the patient. This method provides a targeted approach to selecting the most suitable treatment regimen based on the genetic characteristics of the tumor tissue specimen, ultimately aiming to improve treatment outcomes for patients with colorectal cancer.
To know more about GlobalData’s detailed insights on Yakult Honsha, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
